News and Press Releases
Successful Conclusion of London Biotechnology Show, Leaves Attendees Highly Satisfied
10 May 2024 -- London, UK -- The curtain has closed on the debut London Biotechnology Show 2024, leaving attendees thoroughly impressed by the seamless delivery of promised content and...
Category: Biotechnology
Posted: May 10, 2024
Verisense Health Elects Josh Tolkoff to its Board of Directors
Josh brings extensive medical device, investment and growth management experience to his new role 9 May 2024 -- Massachusetts, US -- Verisense Health, a digital health technology and data company,...
Category: Biotechnology, Other
Posted: May 9, 2024
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
9 May 2024 -- Tokyo, Japan and Cambridge, UK -- Nxera Pharma provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March...
Category: Drug Discovery, Other
Posted: May 9, 2024
DevPro Biopharma and Bespak complete early feasibility studies for new groundbreaking Albuterol Inhaler Ventolin-equivalent pMDI utilides near-zero global warming potential propellant
7 May 2024 – Basking Ridge, NJ, US and Holmes Chapel, UK – DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation...
Category: Drug Delivery, Logistics
Posted: May 9, 2024
Berry To Demonstrate its Patient-Centred Approach at PCI Days 2024
8 May 2024 – Evansville, IN, US – Berry Global’s solutions for patient-centred packaging and drug delivery devices that enhance dosing, administration, and medication adherence will be showcased at this...
Category: Logistics, Manufacturing and Packing
Posted: May 9, 2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...
Category: Biotechnology, Clinical Trials
Posted: May 8, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos Technology Significantly Increases Drug Delivery into Cells
Semaglutide is the active ingredient of weight loss medications Ozempic and Wegovy Semaglutide as an oleogel formulation using the BrainDos technology is internalised much more strongly than in an aqueous...
Category: Drug Delivery, Pharmaceutical
Posted: May 8, 2024
Schynweg 7 Office: St. Anna-Weg 16 P.O.Box 138 6376 Emmetten / Switzerland
First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, New Jersey, US
With the recent FDA approval of LYFGENIA, developed by bluebird bio, Minaris Regenerative Medicine North America is now supporting a commercial cell and gene therapy (CGT) product The first commercial...
Category: BioManufacturing, Biotechnology
Posted: May 8, 2024
Pharma and Regulatory Giants Tackle AI Trust and Legislative Challenges at Largest Ever Pistoia Alliance Annual Conference
Survey of life sciences experts found 70% recognise potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and...
Category: Clinical Trials, Logistics
Posted: May 8, 2024
Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third
8 May 2024 -- Pennsylvania, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship...
Category: Clinical Trials, Other
Posted: May 8, 2024
INTERPHEX 2024 concludes with major success showcasing innovation, knowledge capture, and networking
Norwalk, CT, 23 April 2024 – Norwalk, CA, US – INTERPHEX, the premier, global pharmaceutical and biotechnology trade event concluded last week (16-18 April 2024) following three days of scientifically...
Category: BioManufacturing, Biotechnology, Drug Delivery, Drug Discovery
Posted: May 8, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance
Latest real-world metric in Phesi’s AI-driven Trial Accelerator quantifies patient burden to unlock a patient-centric approach to trial design and implementation 7 May 2024 -- Boston, US -- Phesi, a...
Category: Clinical Trials
Posted: May 7, 2024
Gilead Sciences Appoints Peter Wickersham to Vice-President and General Manager in the UK and Ireland
7 May 2024 -- London, UK -- Gilead Sciences announced today the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
New high-throughput device to unlock the potential of advanced materials
7 May 2024 -- Birmingham, UK -- A Birmingham researcher has developed a new high-throughput device that produces libraries of nanomaterials, using sustainable mechanochemical approaches. Dr Jason Stafford from the...
Category: BioManufacturing
Posted: May 7, 2024
